SBIR-STTR Award

Data acquisition system for noninvasive cancer detection
Award last edited on: 4/26/19

Sponsored Program
STTR
Awarding Agency
NIH : NCI
Total Award Amount
$1,052,292
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Boris Gorbovitski

Company Information

Biophotonics Corporation

25 East Loop Road Suite 110
Stony Brook, NY 11790
   (516) 770-5428
   info@bp.dnalab.cc
   www.biophotonicscorp.com

Research Institution

SUNY Stonybrook

Phase I

Contract Number: 1R42CA106193-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2004
Phase I Amount
$96,386
The overall goal of the proposal is to develop an automated data acquisition system for non-invasive quantitative cancer detection, screening, and monitoring, based on highly sensitive low volume real time PCR technique and capillary electrophoresis, apply this system for quantitative analysis of the telomerase activity and gene expression in single cancer cells, and to validate this system on clinical specimens using exfoliated cancer cells in voided urine of prostate cancer patients. Phase I of the project aims at building the bench-top prototype of the detection system and determination of the limits of sensitivity of the proposed instrument for quantitative measurement of telomerase activity and hTERT mRNA expression in comparison with the sensitivity of one of the best commercial real-time PCR instruments, OpticonTM, MJ Research, available at SUNY core facility, and/or ABI PRISM TM7700, PE Applied Biosystems. In Phase II we will develop an automated pilot prototype of the data acquisition system, validate the instrument using exfoliated cancer cells in voided urine specimens of prostate cancer patients, and develop optimal protocols for clinical sample preparation and analysis.

Thesaurus Terms:
automated data processing, neoplasm /cancer diagnosis, noninvasive diagnosis, prostate neoplasm, technology /technique development enzyme activity, gene expression, telomerase capillary electrophoresis, clinical research, polymerase chain reaction

Phase II

Contract Number: 4R42CA106193-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2005
(last award dollars: 2007)
Phase II Amount
$955,906

The overall goal of the proposal is to develop an automated data acquisition system for non-invasive quantitative cancer detection, screening, and monitoring, based on highly sensitive low volume real time PCR technique and capillary electrophoresis, apply this system for quantitative analysis of the telomerase activity and gene expression in single cancer cells, and to validate this system on clinical specimens using exfoliated cancer cells in voided urine of prostate cancer patients. Phase I of the project aims at building the bench-top prototype of the detection system and determination of the limits of sensitivity of the proposed instrument for quantitative measurement of telomerase activity and hTERT mRNA expression in comparison with the sensitivity of one of the best commercial real-time PCR instruments, OpticonTM, MJ Research, available at SUNY core facility, and/or ABI PRISM TM7700, PE Applied Biosystems. In Phase II we will develop an automated pilot prototype of the data acquisition system, validate the instrument using exfoliated cancer cells in voided urine specimens of prostate cancer patients, and develop optimal protocols for clinical sample preparation and analysis.

Thesaurus Terms:
automated data processing, neoplasm /cancer diagnosis, noninvasive diagnosis, prostate neoplasm, technology /technique development enzyme activity, gene expression, telomerase capillary electrophoresis, clinical research, polymerase chain reaction